Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KUR 501

Next Previous
Drug Profile

KUR 501

Alternative Names: Anti-GD2 CAR NKT cells; CAR-modified NKT-cell therapy; CAR-NKT therapy; CAR.GD2-IL-15 NKTs; Chimeric antigen receptors natural killer T-cells (CAR-NKT) therapy; CMD-501; GINAKIT Cells; KUR-501; KUR-501 GD2 CAR-NKT

Latest Information Update: 16 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine
  • Developer Baylor College of Medicine; Center for Cell and Gene Therapy
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; NKT cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Interleukin 15 replacements; Natural Killer T-cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Neuroblastoma; Small cell lung cancer

Most Recent Events

  • 12 Sep 2023 Discontinued - Phase-I for Neuroblastoma (In adolescents, In children, In infants, Late-stage disease, Second-line therapy or greater, In adults) in USA (Parenteral)
  • 07 Aug 2023 KUR 501 is still in phase-I development in Neuroblastoma (In adolescents, In children, In infants, Late-stage disease, Second-line therapy or greater, In adults) in USA (Parenteral, Infusion) (Kuur Therapeutics, August 2023)
  • 28 May 2023 No recent reports of development identified for phase-I development in Neuroblastoma(In adolescents, In children, In infants, Late-stage disease, Second-line therapy or greater, In adults) in USA (Parenteral, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top